It has been previously demonstrated that insulin-reactive B cells act as antigen-presenting cells to promote type 1 diabetes by stimulating pathogenic T cells and leading to destruction of insulin-producing beta cells of pancreatic islets.
A metabolite that suppresses appetite and food intake after exercise could be the reason for the weight loss observed in patients treated with metformin to control blood glucose. A study conducted by a group of scientists at Stanford University showed how this antidiabetic drug induced the biosynthesis of N-lactoyl-phenylalanine (Lac-Phe), which has an effect reducing the body mass index.
At the ongoing ACS meeting in New Orleans, Rezubio Pharmaceuticals Co. Ltd. detailed the discovery and preclinical evaluation of novel small-molecule gut-restricted GPR40 agonists using membrane-anchored drug (MADD) design.
Fractyl Health Inc. has reported promising new preclinical findings supporting RJVA-001, the first clinical candidate in its Rejuva pancreatic gene therapy platform. The company’s GLP-1 gene therapy candidate has potential to treat metabolic diseases, including obesity and type 2 diabetes.
Creative Medical Technology Holdings Inc.'s Immcelz (CELZ-101) has been awarded orphan drug designation by the FDA. Immcelz is aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation.
Novel nicotinamide phosphoribosyltransferase (NAMPT) positive allosteric modulators (N-PAMs) have been discovered and evaluated by University of Illinois and University of Arizona investigators.
Fractyl Health Inc. has nominated RJVA-001 as the first clinical type 2 diabetes candidate from its Rejuva gene therapy platform, which is designed to deliver locally administered genetic medicines to the pancreas.
Encellin Inc. has announced the closing of a US$9.9 million financing round that will support the company’s development of its cell encapsulation platform with an initial focus on type 1 diabetes.
Preveceutical Medical Inc. is working to accelerate the completion of its preclinical diabetes and obesity dual gene therapy program. The company is pursuing a dual-gene therapy strategy using in vitro validated Smart-siRNA sequences, which when paired with its proprietary bioresponsive lipid-nanoparticulate delivery systems, effectively target the PTPN1 gene.
Lysophosphatidylcholine acyltransferase 3 (LPCAT3), highly expressed in the liver, intestine, and adipose tissues, is an enzyme that preferentially incorporates polyunsaturated fatty acyl chain into lysophospholipids. Previous work showed that LPCAT3 and phospholipid remodeling play a crucial role in regulating glucose metabolism and contribute to the development of insulin resistance in type 2 diabetes.